Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,102 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,640 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,155)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06991738 | 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer | not yet recruiting | Phase 1 / Phase 2 | 18 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07005297 | Clinical Genetics Branch Eligibility Screening Survey | not yet recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07515651 | Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy Using SBRT for Prostate Cancer to Reduce Treatment Toxicity(MIDAS-SBRT) | not yet recruiting | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | not yet recruiting | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07574541 | Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance | not yet recruiting | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07578649 | Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer | not yet recruiting | Phase 3 | 600 | PfizerINDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07691762 | A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 690 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | not yet recruiting | Phase 1 / Phase 2 | 60 | University Health Network, TorontoOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | not yet recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07737314 | Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study | not yet recruiting | N/A | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07740317 | Neurocognitive Trajectories After BCMA CAR-T(CAR-T Cog) | not yet recruiting | — | 50 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor | not yet recruiting | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07836933 | Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL) | not yet recruiting | N/A | 50 | University of California, San FranciscoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07843303 | Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II,Multicenter, Single-Arm Study | not yet recruiting | Phase 2 | 53 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07843433 | ImprovINg the TIMEly Diagnosis and Treatment of Cancer and Cardio-metabolic Diseases in People With Mental Disorders: Reducing Health Disparities Through Integrated Care(IN-TIME) | not yet recruiting | — | 120 | IRCCS San RaffaeleOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07843537 | MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study | not yet recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07844018 | ADC Based Therapy Accroding to HER2 Heterogeneous(HER2level) | not yet recruiting | Phase 2 | 88 | Peking University People's HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844057 | First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma(FIRE-12) | not yet recruiting | Phase 2 | 86 | Annika KurreckOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844291 | A Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast Cancer(SwithADC) | not yet recruiting | N/A | 432 | Peking University People's HospitalOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07844304 | CascadeDiagnose Prostate MRI | not yet recruiting | — | 3,000 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844447 | A Study of RT036 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 308 | Shanghai Ruotuo Biosciences Co., Ltd.INDUSTRY | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07844551 | ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC | not yet recruiting | Phase 2 | 40 | Huashan HospitalOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07844681 | Cyanoacrylate Skin Adhesive After Mohs Surgery or Wide Local Excision | not yet recruiting | N/A | 300 | University of MinnesotaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844759 | SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers(SOLIS) | not yet recruiting | N/A | 30 | Renaissance Institute of Precision Oncology and RadiosurgeryOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07845097 | Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma | not yet recruiting | Phase 2 | 90 | All India Institute of Medical SciencesOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT06744712 | Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients | not yet recruiting | N/A | 130 | Wake Forest University Health SciencesOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07105046 | Facilitators and Barriers to Cancer Treatment Among Texas Residents | not yet recruiting | N/A | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07282444 | A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial(CORRECT) | not yet recruiting | N/A | 194 | Wake Forest University Health SciencesOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07419880 | Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer(RECLAIM) | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07422896 | A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma(Bvax) | not yet recruiting | Phase 1 | 25 | Catalina Lee ChangOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07508358 | Vaginal Sildenafil for Primary Dysmenorrhea(SILDYS) | not yet recruiting | Phase 1 | 10 | Kevin HellmanOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07510906 | Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer(P-PET) | not yet recruiting | N/A | 25 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07558096 | Evaluating Avive+ Soft Tissue Matrix for Prevention of Superficial Radial Nerve Morbidity Following Radial Forearm Free Flap Harvest | not yet recruiting | N/A | 80 | University of Alabama at BirminghamOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07663630 | A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss | not yet recruiting | Phase 1 | 80 | PfizerINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07686367 | Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers | not yet recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07709000 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | not yet recruiting | Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07813585 | Impact of Demography, Ethnicity, Co-morbidities and Inequalities on Outcomes in DLBCL Across the UKCHART Network(DECIPHER) | not yet recruiting | — | 2,000 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07840456 | Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial(InflammaSTOP) | not yet recruiting | Phase 2 | 66 | University Hospital, Basel, SwitzerlandOTHER | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07840534 | Patient-Initiated Follow-Up for Women After Early Breast Cancer Treatment (LYSA2PIFU)(LYSA2PIFU) | not yet recruiting | N/A | 30 | University College CorkOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07840599 | Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients(Fit2ThriveMB) | not yet recruiting | N/A | 224 | Northwestern UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841002 | CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 12 | Liping DouOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841106 | Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases. | not yet recruiting | Phase 2 | 49 | Jiangmen Central HospitalOTHER | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07841704 | NAUTILUS-04: No Axillary Surgical Treatment in Low-Risk Clinically Node-Negative Breast Cancer Without Whole-Breast Radiotherapy - A Prospective, Randomized, Phase III, Non-inferiority Clinical Trial(NAUTILUS-04) | not yet recruiting | N/A | 1,520 | Wonshik HanOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841873 | Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors(ZENITH-01) | not yet recruiting | Phase 2 | 15 | Anhui Provincial HospitalOTHER_GOV | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07841925 | A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842198 | Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy(CARMic) | not yet recruiting | Phase 2 | 150 | Zealand University HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842211 | Feasibility and Validation of an Automated AI-Enabled Deep Ultraviolet (DUV) Cytology Platform for Point-of-Care Oral Cancer Triage(DEEP UV-M) | not yet recruiting | N/A | 270 | Anh LeOTHER | 1 | Sep 25, 2026 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials